Carcinoma, Hepatocellular

• 

  Subject Areas on Research

  • 2017 Version of LI-RADS for CT and MR Imaging: An Update. 
  • A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine. 
  • A farewell to Barcelona Clinic Liver Cancer (BCLC) classification for hepatocellular carcinoma. 
  • A long-term experience with expansion of Milan criteria for liver transplant recipients. 
  • A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. 
  • A pathological fracture and a solitary mass in the right clavicle: an unusual first presentation of HCC and the role of immunohistochemistry. 
  • A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. 
  • A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. 
  • A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. 
  • A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. 
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element. 
  • ACR Appropriateness Criteria® Chronic Liver Disease. 
  • AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. 
  • ALPPS Procedure for Hepatocellular Carcinoma in Patients With Chronic Liver Disease: Revealing a Terra Incognita. 
  • Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. 
  • Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. 
  • Acting in the face of uncertainty. 
  • Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. 
  • Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. 
  • Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. 
  • An update for LI-RADS: Version 2018. Why so soon after version 2017? 
  • Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. 
  • Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. 
  • Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells. 
  • Apoptosis and cytokines in non-alcoholic steatohepatitis. 
  • Artificial intelligence in assessment of hepatocellular carcinoma treatment response. 
  • Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. 
  • Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. 
  • Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. 
  • Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. 
  • Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. 
  • Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. 
  • Autophagic protein ULK1 regulates FOXM1 signalling in human hepatoma cells. 
  • Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list. 
  • Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. 
  • Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. 
  • CD24 as a Novel Predictive Biomarker in Patients with Hepatocellular Carcinoma: Friend or Foe? 
  • CT arterial portography: causes of technical failure and variable liver enhancement. 
  • CT during arterial portography: diagnostic pitfalls. 
  • CT versus MRI in Treatment Response Assessment with LI-RADS: The Choice Is Unclear. 
  • CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. 
  • Can MRI Features of Combined Hepatocellular Carcinoma-Intrahepatic Cholangiogarcinoma Help Predict Tumor Behavior Better than Histologic Findings? 
  • Case 23-2005: a man with a mass in the liver. 
  • Cases from the Osler Medical Service at Johns Hopkins University. 
  • Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. 
  • Challenges in screening for hepatocellular carcinoma in the glycogen storage disease type 1a population. 
  • Challenging choices: liver transplantation for hepatocellular carcinoma. 
  • Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. 
  • Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. 
  • Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. 
  • Cirrhosis of the liver in long-term marrow transplant survivors. 
  • Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. 
  • Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. 
  • Clinical impact of an adaptive statistical iterative reconstruction algorithm for detection of hypervascular liver tumours using a low tube voltage, high tube current MDCT technique. 
  • Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. 
  • Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein. 
  • Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA. 
  • Combined hepatocellular and cystadenocarcinoma presenting as a giant cyst of the liver--a case report. 
  • Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. 
  • Comparison of human and rat hepatocyte metabolism and mutagenic activation of 2-acetylaminofluorene. 
  • Computed tomography of primary liver tumors in children. 
  • Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. 
  • Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. 
  • Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. 
  • Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis. 
  • Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. 
  • DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. 
  • Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. 
  • Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. 
  • Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. 
  • Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance. 
  • Detection of hepatocellular carcinoma in patients with cirrhosis: added value of coronal reformations from isotropic voxels with 64-MDCT. 
  • Detection of liver masses with spiral computed tomography. 
  • Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. 
  • Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. 
  • Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. 
  • Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group. 
  • Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. 
  • Differences in Liver Imaging and Reporting Data System Categorization Between MRI and CT. 
  • Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. 
  • Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors alpha and beta. 
  • Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways. 
  • Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. 
  • Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. 
  • Discovery of Druggable Host Factors Critical to Plasmodium Liver-Stage Infection. 
  • Discussion. 
  • Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. 
  • Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. 
  • Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. 
  • Dual-Energy Multidetector Computed Tomography With Iodine Quantification in the Evaluation of Portal Vein Thrombosis: Is It Possible to Discard the Unenhanced Phase? 
  • Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. 
  • EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells. 
  • Effect of Surgical Margin Width on Patterns of Recurrence among Patients Undergoing R0 Hepatectomy for T1 Hepatocellular Carcinoma: An International Multi-Institutional Analysis. 
  • Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. 
  • Effect of growth conditions on the activity of ornithine decarboxylase in cultured hepatoma cells. I. Effect of amino acid supply. 
  • Effect of growth conditions on the activity of ornithine decarboxylase in cultured hepatoma cells. II. Effect of serum and insulin. 
  • Effect of growth conditions on the ornithine decarboxylase activity of rat hepatoma cells. 
  • Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. 
  • Effect of varying contrast material iodine concentration and injection technique on the conspicuity of hepatocellular carcinoma during 64-section MDCT of patients with cirrhosis. 
  • Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. 
  • Effects of neoplasms on inflammation: depression of macrophage accumulation after tumor implantation. 
  • Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. 
  • Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. 
  • Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. 
  • Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. 
  • Epithelial-mesenchymal transitions and hepatocarcinogenesis. 
  • Estrogen-related receptors stimulate pyruvate dehydrogenase kinase isoform 4 gene expression. 
  • Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. 
  • Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. 
  • Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. 
  • Expression of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study. 
  • External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. 
  • Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? 
  • Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. 
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. 
  • Focal fatty infiltration: a cause of nontumorous defects in the left hepatic lobe during CT arterial portography. 
  • Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? 
  • Four-dimensional magnetic resonance imaging using axial body area as respiratory surrogate: initial patient results. 
  • Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study. 
  • Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. 
  • From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. 
  • Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis. 
  • Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. 
  • Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants. 
  • Gastrohepatic Fistula After Y-90 Embolization of Hepatocellular Carcinoma. 
  • Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. 
  • Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. 
  • Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. 
  • Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. 
  • Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma. 
  • Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? 
  • Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. 
  • Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. 
  • Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. 
  • Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma. 
  • Hepatic adenoma and focal nodular hyperplasia. 
  • Hepatic adenoma: MR appearance mimicking focal nodular hyperplasia. 
  • Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts. 
  • Hepatic imaging characteristics predict overall survival in hepatocellular carcinoma. 
  • Hepatic resection for hepatocellular carcinoma: do contemporary morbidity and mortality rates demand a transition to ablation as first-line treatment? 
  • Hepatitis C. 
  • Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. 
  • Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediate-high risk observations, but not time to progression. 
  • Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. 
  • Hepatocellular Carcinoma Surveillance. 
  • Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. 
  • Hepatocellular adenoma among adult survivors of childhood and young adult cancer. 
  • Hepatocellular adenomas: Understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. 
  • Hepatocellular carcinoma and model for end-stage liver disease exceptions: the more we understand, the more challenging the allocation gets. 
  • Hepatocellular carcinoma arising from ectopic liver tissue in the pancreas. 
  • Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. 
  • Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. 
  • Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? 
  • Hepatocellular carcinoma in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout. 
  • Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. 
  • Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. 
  • Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. 
  • Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. 
  • Hepatocellular carcinoma presenting at contrast-enhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (≤2 cm), indeterminate nodule: growth rate and optimal interval time for imaging follow-up. 
  • Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. 
  • Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature. 
  • Hepatocellular carcinoma. 
  • Hepatocellular carcinoma: clinical and angiographic findings and predictability for surgical resection. 
  • Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity. 
  • Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. 
  • How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? 
  • How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. 
  • Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers. 
  • Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. 
  • Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. 
  • Hypoxia inhibits induction of aryl hydrocarbon receptor activity in topminnow hepatocarcinoma cells in an ARNT-dependent manner. 
  • I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. 
  • Identification of driver genes in hepatocellular carcinoma by exome sequencing. 
  • Ignore reality but not the consequences of its ignorance: Broaden guidelines in surgery of hepatocellular carcinoma. 
  • Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device--initial observations. 
  • Imaging in Patients with Cirrhosis: Current Evidence. 
  • Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. 
  • Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. 
  • Impact of Reference Standard on CT, MRI, and Contrast-enhanced US LI-RADS Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. 
  • Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. 
  • Impact of time-to-surgery on outcomes of patients undergoing curative-intent liver resection for BCLC-0, A and B hepatocellular carcinoma. 
  • Impaired proliferation and tumorigenicity induced by CCAAT/enhancer-binding protein. 
  • Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. 
  • Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. 
  • In vivo guidance and assessment of liver radio-frequency ablation with acoustic radiation force elastography. 
  • In vivo visualization of abdominal malignancies with acoustic radiation force elastography. 
  • In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. 
  • Increased expression of estrogen receptor beta in pachytene spermatocytes after short-term methoxyacetic acid administration. 
  • Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes. 
  • Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinum-based chemoradiotherapy in 76 patients. 
  • Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. 
  • Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study. 
  • Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC. 
  • Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. 
  • Invited Commentary: Key Role of Imaging in Management and Prognosis of Hepatocellular Carcinoma. 
  • Iodized Oil Transarterial Chemoembolization and Radiofrequency Ablation for Small Periportal Hepatocellular Carcinoma: Comparison with Nonperiportal Hepatocellular Carcinoma. 
  • Is diaphragm motion a good surrogate for liver tumor motion? 
  • Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? 
  • LI-RADS 2017: An update. 
  • LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. 
  • LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations: an exploratory study. 
  • LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. 
  • LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data. 
  • LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement. 
  • LI-RADS: a glimpse into the future. 
  • Laparoscopic Hepatectomy for Hepatocellular Carcinoma: The Opportunities, the Challenges, and the Limitations. 
  • Laparoscopic staging for hepatobiliary carcinoma. 
  • Left hepatic trisectionectomy for hepatobiliary malignancy: results and an appraisal of its current role. 
  • Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. 
  • Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. 
  • Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. 
  • Liver and intestine transplantation in the United States 1998-2007. 
  • Liver and intestine transplantation in the United States, 1997-2006. 
  • Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway. 
  • Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. 
  • Liver transplantation for glycogen storage disease type Ia. 
  • Liver transplantation for hepatocellular carcinoma: Management after the transplant. 
  • Liver transplantation for liver malignancies in Wilson's disease: two novel cases. 
  • Liver transplantation for the treatment of hepatocellular carcinoma. 
  • Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. 
  • Liver-specific deletion of augmenter of liver regeneration accelerates development of steatohepatitis and hepatocellular carcinoma in mice. 
  • Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. 
  • Living donor liver transplantation. 
  • Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. 
  • Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. 
  • Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. 
  • Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy. 
  • Long-term outcomes following microwave ablation for liver malignancies. 
  • Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. 
  • Loss of BCAA Catabolism during Carcinogenesis Enhances mTORC1 Activity and Promotes Tumor Development and Progression. 
  • Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. 
  • MR-PET co-registration in upper abdominal imaging: quantitative comparison of two different T1-weighted gradient echo sequences: initial observations. 
  • MR-PET evaluation of 1-month post-ablation therapy for hepatocellular carcinoma: preliminary observations. 
  • MRI-based treatment planning for liver stereotactic body radiotherapy: validation of a deep learning-based synthetic CT generation method. 
  • MRI-based treatment planning for proton radiotherapy: dosimetric validation of a deep learning-based liver synthetic CT generation method. 
  • Macrophage migratory dysfunction in cancer. A mechanism for subversion of surveillance. 
  • Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. 
  • Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations. 
  • Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review. 
  • Mechanisms of disease progression in nonalcoholic fatty liver disease. 
  • Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. 
  • MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma. 
  • Minimal Risk of Biliary Tract Complications, Including Hepatic Abscess, After Transarterial Embolization for Hepatocellular Carcinoma Using Concentrated Antibiotics Mixed with Particles. 
  • Mitochondrial transcription factor A induction by redox activation of nuclear respiratory factor 1. 
  • Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. 
  • Multiphase multi-detector row computed tomography in the setting of chronic liver disease and orthotopic liver transplantation: can a series be eliminated in order to reduce radiation dose? 
  • Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. 
  • Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA. 
  • NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. 
  • Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells. 
  • Nodular regenerative hyperplasia in partial hepatectomy specimens. 
  • Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. 
  • Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern? 
  • Nonalcoholic Fatty Liver Disease and the Gut Microbiome. 
  • Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes. 
  • Novikoff hepatoma deoxyribonucleic acid polymerase. Sensitivity of the beta-polymerase to sulfhydryl blocking agents. 
  • Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. 
  • Nutritional status: its influence on the outcome of patients undergoing liver transplantation. 
  • On confirmation bias in imaging research. 
  • Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. 
  • Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. 
  • Opportunities for targeted therapies in hepatocellular carcinoma. 
  • Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. 
  • Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma. 
  • Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. 
  • Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. 
  • Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. 
  • Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. 
  • Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. 
  • Overexpression of caspase-3 in hepatocellular carcinomas. 
  • Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. 
  • Oxygen flux analysis to understand the biological function of sirtuins. 
  • PGC-1beta in the regulation of hepatic glucose and energy metabolism. 
  • Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. 
  • Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. 
  • Pathology and imaging of hepatocellular neoplasms: are findings from Asian populations applicable to non-Asian groups? 
  • Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. 
  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. 
  • Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. 
  • Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. 
  • Physician-assisted suicide and advance directives concerning life support. 
  • Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. 
  • Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. 
  • Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. 
  • Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-Hepatocellular Carcinoma Factors. 
  • Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI. 
  • Predicting recurrence patterns after resection of hepatocellular cancer. 
  • Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. 
  • Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. 
  • Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. 
  • Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. 
  • Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis. 
  • Primary hepatic neoplasms arising in cirrhotic livers can have a variable spectrum of neuroendocrine differentiation. 
  • Problems for risk assessment of endocrine-active estrogenic compounds. 
  • Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. 
  • Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. 
  • Progression of Treated versus Untreated Liver Imaging Reporting and Data System Category 4 Masses after Transcatheter Arterial Embolization Therapy. 
  • Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. 
  • Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. 
  • Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. 
  • Quantitative mass spectrometry of DENV-2 RNA-interacting proteins reveals that the DEAD-box RNA helicase DDX6 binds the DB1 and DB2 3' UTR structures. 
  • RIFLE criteria and hepatic function in the assessment of acute renal failure in liver transplantation. 
  • RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer. 
  • Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. 
  • Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. 
  • Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin. 
  • Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. 
  • Radiofrequency ablation of liver tumors: influence of technique and tumor size. 
  • Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. 
  • Rapid degradation of puromycyl peptides in hepatoma cells and reticulocytes. 
  • Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. 
  • Reassessing hepatocellular carcinoma staging in a changing patient population. 
  • Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. 
  • Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al. 
  • Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy. 
  • Ring finger protein 121 is a potent regulator of adeno-associated viral genome transcription. 
  • Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. 
  • Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. 
  • Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis. 
  • Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. 
  • Role of computed tomography in screening for hepatocellular carcinoma in patients with cirrhosis. 
  • Role of exosomes in treatment of hepatocellular carcinoma. 
  • Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. 
  • Serum α-Fetoprotein Levels at Time of Recurrence Predict Post-Recurrence Outcomes Following Resection of Hepatocellular Carcinoma. 
  • Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. 
  • Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. 
  • Spectrum of Pitfalls, Pseudolesions, and Potential Misdiagnoses in Cirrhosis. 
  • Stemming the tide of hepatitis B virus related hepatocellular carcinoma? 
  • Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities. 
  • Stereotactic Body Radiation Therapy-Induced Abscopal Effect on Hepatocellular Carcinoma After Treatment for Lung Cancer: A Case Report. 
  • Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging. 
  • Surgical clearance for the patient with chronic liver disease. 
  • Surgical resection for benign and malignant liver disease. 
  • Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. 
  • Surveillance for hepatocellular carcinoma. 
  • Sustained expression of human factor VIII in mice using a parvovirus-based vector. 
  • TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. 
  • Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma. 
  • Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy? 
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. 
  • Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. 
  • Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. 
  • The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. 
  • The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. 
  • The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. 
  • The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE. 
  • The Role of Angiogenesis in Hepatocellular Carcinoma. 
  • The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. 
  • The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. 
  • The effect of Guidelines in surgical decision making: The paradigm of hepatocellular carcinoma. 
  • The effect of protein nutrition on host and tumor metabolism. 
  • The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. 
  • The effects of hepatic cryosurgery on tumor growth in the liver. 
  • The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. 
  • The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. 
  • The induction of ornithine decarboxylase in cultured hepatoma cells. 
  • The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. 
  • The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma. 
  • The natural history of hepatitis C viral infection. 
  • The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? 
  • The role of external beam radiotherapy in the treatment of hepatocellular cancer. 
  • The struggle for intensive care coverage of patients with hepatobiliary malignancies in Greece: Patients are not numbers. 
  • The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells. 
  • The unique identity of rat hepatoma phenylalanine hydroxylase. 
  • Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. 
  • Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. 
  • Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. 
  • Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. 
  • Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. 
  • Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? 
  • Trends in the Mortality of Hepatocellular Carcinoma in the United States. 
  • Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. 
  • U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. 
  • Understanding Factors Governing Distribution Volume of Ethyl Cellulose-Ethanol to Optimize Ablative Therapy in the Liver. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. 
  • User and system pitfalls in liver imaging with LI-RADS. 
  • Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. 
  • Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. 
  • V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. 
  • Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. 
  • Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. 
  • Value of PET/CT in the management of primary hepatobiliary tumors, part 2. 
  • Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. 
  • Vitamins E and K induce aryl hydrocarbon hydroxylase activity in human cell cultures. 
  • White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. 
  • Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. 
  • Without victory there is no survival: transarterial lipiodol chemoembolization and hepatocellular carcinoma. 
  • Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. 
  • c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. 
  • p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. 
• 

  Keywords of People

  • Choi, Steven Sok, Associate Professor of Medicine, Medicine, Gastroenterology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Pharmacology & Cancer Biology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics